ES2170857T3 - Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato. - Google Patents

Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.

Info

Publication number
ES2170857T3
ES2170857T3 ES96916266T ES96916266T ES2170857T3 ES 2170857 T3 ES2170857 T3 ES 2170857T3 ES 96916266 T ES96916266 T ES 96916266T ES 96916266 T ES96916266 T ES 96916266T ES 2170857 T3 ES2170857 T3 ES 2170857T3
Authority
ES
Spain
Prior art keywords
trihydrate
methanosulfonate
hydroxi
phenylpiperidin
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96916266T
Other languages
English (en)
Inventor
Marta M Andino
Terry G Sinay
Eugene F Fiese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2170857T3 publication Critical patent/ES2170857T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION SE REFIERE AL TRIHIDRATO DE LA SAL MESILATO DE (1S,2S) NILPIPERIDIN ACEUTICAS QUE LA CONTIENEN Y A LOS METODOS DE USARLA EN EL TRATAMIENTO DE TRASTORNOS DEL SNC.
ES96916266T 1995-08-11 1996-06-20 Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato. Expired - Lifetime ES2170857T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
ES2170857T3 true ES2170857T3 (es) 2002-08-16

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96916266T Expired - Lifetime ES2170857T3 (es) 1995-08-11 1996-06-20 Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.

Country Status (41)

Country Link
US (1) US6008233A (es)
EP (1) EP0843661B1 (es)
JP (1) JP3099072B2 (es)
KR (1) KR100291882B1 (es)
CN (2) CN1615861A (es)
AP (1) AP755A (es)
AR (1) AR004676A1 (es)
AT (1) ATE215072T1 (es)
AU (1) AU710984B2 (es)
BG (1) BG63678B1 (es)
BR (1) BR9610766A (es)
CA (1) CA2228752C (es)
CO (1) CO4750830A1 (es)
CZ (1) CZ296236B6 (es)
DE (1) DE69620191T2 (es)
DK (1) DK0843661T3 (es)
DZ (1) DZ2083A1 (es)
ES (1) ES2170857T3 (es)
GT (1) GT199600051A (es)
HR (1) HRP960372B1 (es)
HU (1) HUP9802862A3 (es)
IL (1) IL122649A (es)
IS (1) IS1945B (es)
MA (1) MA23957A1 (es)
NO (1) NO310458B1 (es)
NZ (1) NZ309134A (es)
OA (1) OA10664A (es)
PE (1) PE4898A1 (es)
PL (1) PL185603B1 (es)
PT (1) PT843661E (es)
RO (1) RO120134B1 (es)
RS (1) RS49521B (es)
RU (1) RU2140910C1 (es)
SA (1) SA96170171B1 (es)
SK (1) SK284209B6 (es)
TN (1) TNSN96104A1 (es)
TR (1) TR199800208T1 (es)
TW (1) TW495502B (es)
UA (1) UA59341C2 (es)
WO (1) WO1997007098A1 (es)
ZA (1) ZA966760B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201106T3 (es) * 1994-08-18 2004-03-16 Pfizer Inc. Derivados neuroprotectores de 3-(piperidinil-1)-croman-4,7-diol y 1-(4-hidrofenil)-2-(piperidinil-1)-alcanol.
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27801A (sh) 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
AU8339301A (en) * 2000-08-16 2002-02-25 Upjohn Co Compounds for the treatment of addictive disorders
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
PT1437353E (pt) 2001-10-19 2007-08-28 Toyama Chemical Co Ltd Derivados de éter de alquilo ou os seus sais.
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EP2597087B1 (en) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
ES2590038T5 (es) 2009-12-11 2021-10-19 Shionogi & Co Derivado de oxazina
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
EP3194403B1 (en) 2014-09-15 2019-02-06 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
WO2016049048A1 (en) * 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
EP3253761A4 (en) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
ES2201106T3 (es) * 1994-08-18 2004-03-16 Pfizer Inc. Derivados neuroprotectores de 3-(piperidinil-1)-croman-4,7-diol y 1-(4-hidrofenil)-2-(piperidinil-1)-alcanol.
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat

Also Published As

Publication number Publication date
HUP9802862A3 (en) 1999-05-28
TR199800208T1 (es) 1998-05-21
ATE215072T1 (de) 2002-04-15
TNSN96104A1 (fr) 2005-03-15
CZ296236B6 (cs) 2006-02-15
DK0843661T3 (da) 2002-07-22
EP0843661A1 (en) 1998-05-27
JPH10510552A (ja) 1998-10-13
AR004676A1 (es) 1999-03-10
RS49521B (sr) 2006-10-27
HRP960372A2 (en) 1998-04-30
EP0843661B1 (en) 2002-03-27
MA23957A1 (fr) 1997-04-01
BR9610766A (pt) 1999-07-13
PT843661E (pt) 2002-07-31
BG102289A (en) 1998-09-30
DZ2083A1 (fr) 2002-10-23
OA10664A (en) 2000-11-06
DE69620191D1 (de) 2002-05-02
CO4750830A1 (es) 1999-03-31
IL122649A (en) 2001-08-26
IS4643A (is) 1997-12-30
PE4898A1 (es) 1998-03-16
AU5908496A (en) 1997-03-12
BG63678B1 (bg) 2002-09-30
RU2140910C1 (ru) 1999-11-10
AP9600856A0 (en) 1996-10-31
AP755A (en) 1999-08-02
RO120134B1 (ro) 2005-09-30
UA59341C2 (uk) 2003-09-15
NO980574D0 (no) 1998-02-10
PL185603B1 (pl) 2003-06-30
HRP960372B1 (en) 2003-04-30
NZ309134A (en) 1999-09-29
JP3099072B2 (ja) 2000-10-16
CN1198739A (zh) 1998-11-11
SA96170171B1 (ar) 2006-05-20
DE69620191T2 (de) 2002-07-18
KR100291882B1 (ko) 2001-10-26
AU710984B2 (en) 1999-10-07
GT199600051A (es) 1997-12-26
WO1997007098A1 (en) 1997-02-27
MX9801149A (es) 1998-05-31
US6008233A (en) 1999-12-28
SK16698A3 (en) 1999-06-11
KR19990036321A (ko) 1999-05-25
CA2228752A1 (en) 1997-02-27
NO310458B1 (no) 2001-07-09
CN1615861A (zh) 2005-05-18
TW495502B (en) 2002-07-21
CA2228752C (en) 2002-12-10
YU46196A (sh) 1999-07-28
HUP9802862A2 (hu) 1999-04-28
SK284209B6 (en) 2004-11-03
IS1945B (is) 2004-08-13
IL122649A0 (en) 1998-08-16
ZA966760B (en) 1998-02-09
PL325050A1 (en) 1998-07-06
NO980574L (no) 1998-02-10
CZ39098A3 (cs) 1999-02-17

Similar Documents

Publication Publication Date Title
ES2170857T3 (es) Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.
CY1111965T1 (el) Βελτιωμενη συσκευη λεϊζερ χειρος για θεραπευτικη αγωγη του δερματος
ES2156413T3 (es) Sifon autocebante, especialmente para riego.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
ES2099686T1 (es) Composicion de aminoazucar y glicosaminoglicano para el tratamiento y reparacion de tejido conjuntivo.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ES2070830T3 (es) Sistema antimicrobiano de amplio espectro para un limpiador de superficies duras.
ES2105525T3 (es) 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
DE59911408D1 (de) Instrument zum applizieren von licht, insbesondere laserlicht, im menschlichen oder tierischen körper
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
AR023511A1 (es) Composicion que comprende (s) y (r) 5-amino-3-ciano-1-(2,6-dicloro-4-trifluorometilfenil)-4-trifluoro-metilsulfinilpirazol, dichos compuestos aislados y usos de los mismos como plaguicida
ES2146423T3 (es) Procedimiento para la preparacion de disulfuros y polisulfuros organicos en presencia de resinas de poliestireno-divinilbenceno (ps-dvb) que tienen grupos de guanidina o de amidina.
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
DE59504918D1 (de) Direktziehendes haarfärbemittel
ES2053501T3 (es) Agentes coccidiocidas.
FR2725315B1 (fr) Appareil laser a emission pulsee, utilise dans le domaine medical
NO874241D0 (no) Terapeutisk aktive salter.
MX9204286A (es) Agentes para el tratamiento de semillas.
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
ES2132754T3 (es) Preparacion de compuestos halogenados.
SU959976A1 (ru) Импульсный источник питани
UY26519A1 (es) " tratamiento del dolor".
ES2066740B1 (es) Procedimiento de tratamiento de aguas residuales en un puesto de depuracion con el fin de eliminar las molestias olfativas.
ITBO930226A0 (it) Apparecchiatura per trattamenti di emodiafiltrazione.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 843661

Country of ref document: ES